Clinical reference Biomarker Directory
Back to directory

Carbohydrate Antigen 19-9

Established

CA 19-9 is the best-validated pancreatic cancer marker, but is falsely low/undetectable in Lewis-antigen-negative patients.

Also known as CA 19-9 sialyl Lewis A antigen
In plain language

CA 19-9 is the main blood test for pancreatic cancer, but about 1 in 10-20 people can't produce it at all due to their blood type genetics, so a normal result doesn't rule out cancer in those people. It's best used to track treatment, not to screen for cancer.

Biomarker & context

CA 19-9 is a carbohydrate tumor antigen and the best-validated serum biomarker for pancreatic cancer, though it is also elevated in various benign and other malignant conditions.

What it indicates

Elevated CA 19-9 supports pancreatic cancer diagnosis and is used for prognosis, monitoring treatment response, and detecting recurrence; however, its secretion depends on Lewis blood group antigen expression, creating a significant diagnostic gap.

Diagnosis & clinical testing

Roughly 5-10% of the population is Lewis antigen-negative and cannot produce CA 19-9 even with advanced pancreatic cancer, meaning these patients can have falsely low or undetectable levels despite significant disease — a genuine trap for anyone relying on this marker alone. No major guideline (ASCO, NCCN, USPSTF) recommends CA 19-9 for cancer screening.

Guiding treatment

Postoperative CA 19-9 normalization or a 20-50% decrease from baseline after resection or chemotherapy is associated with prolonged survival; its real value is postoperative monitoring and treatment response tracking, not detection or screening.

Clinical significance

A genuine false-negative trap exists in 5-10% of the population due to Lewis blood group status.

References
  1. Luo, G., et al. (2018). New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer. Pancreatology.
  2. PMC. (2011). Serum CA 19-9 as a Biomarker for Pancreatic Cancer.